Assessing Exelixis (EXEL) Valuation After Analysts Lift 2026 Earnings Forecasts

Exelixis (EXEL) is back on investor radars after six analysts raised their earnings forecasts for fiscal 2026, citing the company’s oncology pipeline and their growth expectations as key reasons for the revised outlook.

See our latest analysis for Exelixis.

Even with the recent analyst optimism, Exelixis’ shares have cooled slightly, with a 30 day share price return of a 4.21% decline and a year to date share price return of a 5.53% decline. At the same time, the 1 year total shareholder return of 11.88% and 3 year total shareholder return of 132.73% point to momentum that has built over a longer horizon.

If this oncology story has you thinking about what else is moving in high growth areas, now could be a good time to scan 34 healthcare AI stocks for your next idea.

With earnings forecasts being lifted and the share price still sitting below analyst targets, the key question is whether Exelixis is trading at a discount or whether the market is already factoring in the next phase of growth.

Most Popular Narrative: 12.1% Undervalued

With Exelixis last closing at $41.17 against a narrative fair value of $46.83, the current setup puts that widely followed story to the test.

The company's substantial free cash flow, strong balance sheet, and disciplined capital allocation (including aggressive share repurchases and prioritization of high-probability, high-value R&D programs) position Exelixis to invest in next-generation discovery and strategic partnerships, which has the potential to improve operating leverage and net margins over time as the product portfolio scales.

Read the complete narrative.

Curious how this cash rich oncology player gets to that higher fair value? The narrative focuses on rising margins, measured growth, and a future earnings multiple that may surprise you.

Result: Fair Value of $46.83 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this depends on key risks, including Exelixis' heavy reliance on CABOMETYX and the possibility that competitive drugs or trial setbacks could pressure future earnings assumptions.

Find out about the key risks to this Exelixis narrative.

Next Steps

Does this mixed picture of risks and rewards match how you see Exelixis right now, or not quite yet? Act while the data is fresh and shape your own view by weighing 4 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Exelixis has sharpened your focus, do not stop here. Broaden your watchlist with fresh ideas that line up with how you like to invest.

• Target potential upside by scanning screener containing 25 high quality undiscovered gems that combine solid fundamentals with stories the broader market may not be focused on yet.
• Prioritize resilience by reviewing 68 resilient stocks with low risk scores that score well on our risk checks if you want steadier sleep at night.
• Strengthen your income stream by assessing 15 dividend fortresses that pair higher yields with business profiles built around regular cash returns.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com